1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 31ST DECEMBER 2012.

  (Rupees in '000')
S. No. Particulars Un -audited Un-audited Audited
Quarter Ended Nine Month Ended Year
31.Dec.12 30.Sep.12 31.Dec.11 31.Dec.12 31.Dec.11 31.Mar.12
PART-l (a)Income from Operation            
1 Gross Sales
16,927
19,157 17,496 59,338 57,230 70,455
  less Excise Duty 1,191 1,264 1,000 4,003 2,926 4,435
  Net Sales/Income From Operation
15,736
17,893
16,496
55,335
54,304
66,020
  (b) Other Operating Income 323 - - 323 - -
  Total Income from Operation 16,059 17,893 16,496 55,658 54,304 66,020
2 Expenses            
  (a) Cost Of Material Consumed 5,178 7,088 4,587 18,249 17,656 24,418
  (b) Purchase of Stock in Trade 942 1,504 483 4,316 2,521 3,457
  (c) Change in Inventories Of Finished Goods and Work in Progress of Stock in trade (897) (2,224) 1,473 (732) 3,926 (1,095)
  (d) Employee Benefit Expenses 6,709 6,592 6,313 20,182 17,934 22,545
  (e) Depreciation & Amortisation Expenses 653 653 644 1,960 1,933 2,599
  (f) Other Expenses 2,905 3,509 2,329 9,527 8,417 11,694
  Total Expenses 15,490 17,122 15,829 53,502 52,387 63,618
3 Profit/(Loss) from Operation Before Other Income ( 1-2) 569 771 667 2,156 1,917 2,402
4 Other Income 53 248 55 508 209 369
5 Profit /(Loss) from ordinary activities before 622 1,019 722 2,664 2,126 2,771
  finance cost & Exception items ( 3+4)            
6 Finance Cost 474 542 526 1,553 1,324 1,893
7 Profit /(Loss) from ordinary activities after finance Cost but before Exceptional items ( 5-6) 148 477 196 1,111 802 878
8 Exceptional items - -   - - 158
9 Profit /(Loss) from ordinary activities before Tax ( 7-8) 148 477 196 1,111 802 878
10 Tax Expenses ( Provision for Taxation ) Current tax - - - - - 158
  Deffered tax - - - - - (384)
11 Net Profit/(Loss) From Ordinary Activities after Tax (9-10) 148 477 196 1,111 802 1,104
12 Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears] 354,35 354,35 354,35 354,35 354,35 354,35
13

Reserves Excluding Revaluation Reserves

- - - - - 7,630
14

Earning per share (EPS) before extraordinary item( not Annualised)

- - - - - -
  i) Basic & Diluted - - - - - 0.24
  ii) Diluted - - - - - -
PART-ll

PARTICULARS OF SHAREHOLDING

           
1 Public shareholding            
  i Number of Shares
2,904,901
2,904,901
3,080,150
2,904,901
3,080,150
2,902,900
  ii Percentage of shareholding
63.55%
63.55%
67.38%
63.55%
67.38%
63.51%
2 Promoters and promoter group Shareholding
  a) Pledged/Encumbered
  i Number of shares
  ii Percentage of shares (as a % of the total shareholding of promoter and promoter group)
  iii Percentage of shares (as a% of the total share capital of the company)
  b) Non-encumbered
  - Number of Shares
1,666,099
1,666,099
1,490,850
1,666,099
1,490,850
1,668,100
  - Percentage of shares (as a% of the total shareholding of promoter and promoter group)
36.45%
36.45%
32.62%
36.45%
32.62%
36.49%
  Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
100%

 

B. INVESTORS COMPLAINTS 3 Months ended 31.12.2012
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 31-01-2013
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.01.2013 Chairman & Managing Director

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in